Medline (NASDAQ:MDLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Medline (NASDAQ:MDLN) have been given a consensus rating of “Moderate Buy” by the twenty-nine analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $50.5385.

Several equities research analysts recently weighed in on MDLN shares. Citigroup decreased their price target on Medline from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft set a $42.00 price objective on shares of Medline in a research report on Thursday, May 7th. Weiss Ratings cut shares of Medline from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 15th. Sanford C. Bernstein dropped their price target on shares of Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Barclays cut their price target on shares of Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Monday, June 1st.

Insider Activity at Medline

In related news, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the sale, the insider directly owned 23,899 shares in the company, valued at $878,766.23. The trade was a 80.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jessi L. Corcoran acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $34.15 per share, for a total transaction of $170,750.00. Following the acquisition, the insider directly owned 5,000 shares of the company’s stock, valued at $170,750. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.81% of the company’s stock.

Hedge Funds Weigh In On Medline

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after acquiring an additional 254 shares during the last quarter. North Star Investment Management Corp. grew its position in shares of Medline by 60.2% in the first quarter. North Star Investment Management Corp. now owns 1,362 shares of the company’s stock valued at $61,000 after purchasing an additional 512 shares during the last quarter. Sound Income Strategies LLC purchased a new position in shares of Medline during the 4th quarter worth approximately $25,000. Entrust Financial LLC purchased a new position in shares of Medline during the 4th quarter worth approximately $26,000. Finally, NBC Securities Inc. acquired a new position in shares of Medline during the 4th quarter worth approximately $28,000.

Medline Trading Up 0.5%

NASDAQ MDLN opened at $41.04 on Monday. The firm’s fifty day moving average is $38.07 and its two-hundred day moving average is $42.18. Medline has a one year low of $32.81 and a one year high of $50.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41. The firm has a market cap of $53.91 billion and a PE ratio of 128.25.

Medline (NASDAQ:MDLN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion for the quarter. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. Analysts expect that Medline will post 1.49 earnings per share for the current year.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.